Publication Name	World Journal of Methodology
Manuscript ID	21044
Country	Costa Rica

Received	2015-06-28 18:19
Peer-Review Started	2015-07-05 16:33
First Decision by Editorial Office Director
Return for Revision	2015-08-09 20:53
Revised	2015-08-21 17:30
Publication Fee Transferred
Second Decision by Editor	2015-09-29 17:28
Second Decision by Editor-in-Chief	2015-09-29 19:45
Final Decision by Editorial Office Director	2015-10-13 17:33
Articles in Press	2015-10-13 17:33
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-12-03 13:14
Publish the Manuscript Online	2015-12-15 10:10

ISSN	2222-0682 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Minireviews
Article Title	Monitoring anticoagulant therapy with new oral agents
Manuscript Source	Invited Manuscript
All Author List	Allan Ramos-Esquivel
Funding Agency and Grant Number
Corresponding Author	Allan Ramos-Esquivel, MD, MSc, Department of Pharmacology, School of Medicine, University of Costa Rica, Sede Rodrigo Facio, San Pedro Calle 27, San José 11501-2060, Costa Rica. allanramoscr@gmail.com
Key Words	Anticoagulant agents; Apixaban; Dabigatran; Drug monitoring; Rivaroxaban
Core Tip	New oral anticoagulants are replacing oral vitamin K antagonists for some practical advantages, like unnecessary monitoring and a better pharmacokinetic profile. Nevertheless, in some circumstances, their anticoagulant activity must be monitored in order to prevent adverse outcomes. In this minireview a list of the available laboratory test are reviewed to better understand the pros and cons of each analysis.
Publish Date	2015-12-15 10:10
Citation	Ramos-Esquivel A. Monitoring anticoagulant therapy with new oral agents. World J Methodol 2015; 5(4): 212-215
URL	http://www.wjgnet.com/2222-0682/full/v5/i4/212.htm
DOI	http://dx.doi.org/10.5662/wjm.v5.i4.212

Full Article (PDF)	WJM-5-212.pdf
Full Article (Word)	WJM-5-212.doc
Manuscript File	21044-Review.docx
Answering Reviewers	21044-Answering reviewers.pdf
Audio Core Tip	21044-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	21044-Conflict-of-interest statement.pdf
Copyright License Agreement	21044-Copyright assignment.pdf
Peer-review Report	21044-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	21044-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	21044-Scientific misconduct check.pdf
Scientific Editor Work List	21044-Scientific editor work list.pdf